This delay is particularly critical for patients with advanced maternal age (AMA) or diminished ovarian reserve (DOR), for whom any postponement may result in an irreversible decline in reproductive potential
Obstructive Sleep Apnea SURMOUNT-OSA trials investigated GLP2 in adults with moderate-to-severe obstructive sleep apnea and obesity: Significant improvements in apnea-hypopnea index (AHI) from baseline Benefits observed in participants both using and not using positive airway pressure therapy Improvements correlated with weight reduction FDA approval granted in December 2024 for moderate-to-severe OSA treatment Diabetes Prevention Extended follow-up from SURMOUNT-1 assessed diabetes prevention in participants with prediabetes: 94% reduction in progression to type 2 diabetes compared to placebo over 3 years Nearly all participants with prediabetes at baseline converted to normoglycemia Effects diminished during off-treatment follow-up period, indicating ongoing treatment benefit [CALLOUT BOX Highlighted] Important Context: While GLP2 has demonstrated substantial efficacy in multiple large-scale clinical trials, the majority of data comes from industry-sponsored studies with relatively short follow-up periods (40-72 weeks for most trials)
Caution should be exercised in patients with a history of pancreatitis, as acute pancreatitis has been reported in some patients treated with GLP-1 agonists
This rescue was observed in a fraction of the animals, possibly due to the variable expression levels of TAX6 that is expressed from an extrachromosomal array
Their team explains differences, options, and expected outcomes
This approach allowed for the integration of different types of evidence, broadening the understanding of the drugs clinical performance and safety profile in controlled and real-world settings
